CBP is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor

Molecular Endocrinology

Volumn 22, Issue 2, 2008, Pages 263-272

  Nettles, Kendall W ^a   Gil, German ^a   Nowak, Jason ^a   Métivier, Raphaël ^b   Sharma, Vandana B ^c   Greene, Geoffrey L ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CNRS   (France)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BLOTTING, NORTHERN; CARRIER PROTEINS; CELL LINE, TUMOR; CHEMOKINE CCL2; CHROMATIN IMMUNOPRECIPITATION; CREB-BINDING PROTEIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-6; INTERLEUKIN-8; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NF-KAPPA B; POLYMERASE CHAIN REACTION; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38749144353     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0324     Document Type: Article

References (31)

1. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA 2005 Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 26:465-478
2. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith Jr JC, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC 2005 Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci USA 102:2543-2548
3. Jimi E, Ghosh S 2005 Role of nuclear factor-κB in the immune system and bone. Immunol Rev 208:80-87
4. Ghosh S, Karin M 2002 Missing pieces in the NF-κB puzzle. Cell 109 (Suppl):S81-S96
5. Hayden MS, Ghosh S 2004 Signaling to NF-κB. Genes Dev 18:2195-2224
6. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T 1999 Transcriptional activation by NF-κB requires multiple coactivators. Mol Cell Biol 19:6367-6378
7. Zhong H, Voll RE, Ghosh S 1998 Phosphorylation of NF-κ B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1:661-671
8. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T 1997 Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J Biol Chem 272:31092-31099
9. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K 2000 Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282-3289
10. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M 2001 Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92:1085-1091
11. MacDermott RP 1999 Chemokines in the inflammatory bowel diseases. J Clin Immunol 19:266-272
12. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D 1991 Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256
13. Sumino H, Ichikawa S, Kasama S, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M 2005 Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 28:579-584
14. Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon III RO 2000 Competition for p300 regulates transcription by estrogen receptors and nuclear factor-κB in human coronary smooth muscle cells. Circ Res 87:1006-1011
15. Inadera H, Sekiya T, Yoshimura T, Matsushima K 2000 Molecular analysis of the inhibition of monocyte chemoattractant protein-1 gene expression by estrogens and xenoestrogens in MCF-7 cells. Endocrinology 141:50-59
16. Wissink S, van Heerde EC, vand der Burg B, van der Saag PT 1998 A dual mechanism mediates repression of NF-κB activity by glucocorticoids. Mol Endocrinol 12:355-363
17. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK 2000 The role of CBP in estrogen receptor cross-talk with nuclear factor-κB in HepG2 cells. Endocrinology 141:3403-3411
18. Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Winneker RC, Eckert A, Borges-Marcucci L, Adelman SJ, Xu Z, Mosyak L, Harnish DC 2006 Control of chronic inflammation with pathway selective estrogen receptor ligands. Curr Top Med Chem 6:103-111
19. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM 2002 Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA 99:14789-14794
20. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM, Yao TP 2000 Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14:272-277
21. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R 1998 Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372
22. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763
23. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
24. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG 2000 Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 275:25322-25329
25. Kraus WL, Manning ET, Kadonaga JT 1999 Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol Cell Biol 19:8123-8135
26. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC 2006 Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21:555-564
27. Teyssier C, Belguise K, Galtier F, Chalbos D 2001 Characterization of the physical interaction between estrogen receptor α and JUN proteins. J Biol Chem 276:36361-36369
28. Rogatsky I, Zarember KA, Yamamoto KR 2001 Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20:6071-6083
29. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekamá RCM, Masunoá M, Tommerup N, van Ommen G-JB, Goodman RH, Peters DJM, Breuning MH 1995 Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:348-351
30. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
31. Shah N, Thomas TJ, Lewis JS, Klinge CM, Shirahata A, Gelinas C, Thomas T 2001 Regulation of estrogenic and nuclear factor κ B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene 20:1715-1729